MRK Merck & Co., Inc.
Trend channel, buy level and 3-month target. Information only, not financial advice.
Inside the channel · 18-month channel rising
Price is between the lines.
- 18-month channel
- US$145.11 – US$161.92 · rising, +67% a year
- Price in channel
- 26% (0% = floor, 100% = ceiling)
- Ceiling overhead
- US$161.92
- Turns bearish below
- US$145.11
- Published levels
- Buy and target are not from this channel — see below.
Price history, with the path projected 3 months forward
Updated 6:36 PM ET (17 h ago)
- Daily close
- Upper trend line (18 months)
- Lower trend line (18 months)
- Dashed after today: projected 3 months
- Our buy
- Our target
Our target
Hit rate too low on this symbol (1/6) — no published call or alerts; levels below are for reference.
Buy at or below
US$141.83
level as at 14 Nov 2026
Our target
US$158.85
by 30 Nov 2026
Projected move
12.0%
gross, before costs
Price is between our buy and target.
Target: MRK's usual move size (12.0%), the best return per day on this path.
6 settled calls · 1 reached target (16.7%) · average best move 5.6%. See the full record.
- Upper line touches
- 4
- Lower line touches
- 5
- Fit confidence
- 31%
- Fitted
- 1 Nov 2026
Company information
About Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis
- Employees
- 74,000
- Country
- US
Scorecard
Our own scores from the fundamentals below (not Morningstar ratings).
- Valuation
- —
- Profitability
- —
- Financial health
- —
- Cash generation
- —
Key statistics
- Market cap
- US$355.49B
- Enterprise value
- —
- Beta
- 0.23
- Avg volume
- 10.17M
- Revenue per share
- —
- Dividend yield
- —
- 52-week range
- 77.58-156.92
- Exchange
- NYSE
Key ratios
- P/E (TTM)
- —
- PEG
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Current ratio
- —
- Quick ratio
- —
- Debt / equity
- —
- Interest cover
- —
Income statement
Balance sheet
Cash flow
Trend lines are fitted to past swing highs and lows and may not continue. Information only, not financial advice.